Testosterone Lotion Approval Propels Acrux to Record
This article is for subscribers only.
Acrux Ltd., the developer of an underarm testosterone lotion with Eli Lilly & Co., rose to a record in Australian trading after the treatment was approved for sale in the U.S.
Acrux rose 9.1 percent to A$3.36 as of the 4:10 p.m. close in Sydney, the highest level since the shares listed in September 2004. The stock earlier surged as much as 18 percent.